Translational Strategies for Development of Antibody-Based Therapeutics: An Overview

  • Mohammad Tabrizi
  • Gadi Gazit Bornstein
  • Scott L. Klakamp


With scientific advances, it is possible to rapidly and effectively generate highly tailored and specific antibody-based therapeutics that interact with a diverse array of soluble or cell-associated target antigens. Much like traditional small molecule drugs, a major challenge during the development of antibody-based therapeutics is maintaining an effective information flow and translation of accumulated knowledge throughout the various development phases. The design of effective translational strategies from the early stages of the development process for antibody-based therapeutics is not only necessary to lessen the development time and cost, but also to foster implementation of rational decision making processes throughout various development phases. In this book, we have attempted to provide a comprehensive discussion of various topics critical for establishing successful translational strategies for the development of antibody-based therapeutics.


Target Antigen Therapeutic Antibody Translational Strategy Antibody Variable Region Drug Development Phase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Mohammad Tabrizi
    • 1
  • Gadi Gazit Bornstein
    • 2
  • Scott L. Klakamp
    • 3
  1. 1.Merck Research LaboratoryPalo AltoUSA
  2. 2.Centers for Therapeutic Innovation (CTI) Pfizer IncNew YorkUSA
  3. 3.Biological SciencesTakeda California, IncSan FranciscoUSA

Personalised recommendations